73,205 views
A combination of the molecule Apalutamide and hormonal therapy offers patients with metastatic prostate cancer a 50% reduction in the risk of death and a delay in the use of chemotherapy. Interview with Dr. Rosemarie Gidekel. Director of Medical Affairs for Oncology at Janssen Latam